Sugi Predict

Sugi Predict / Compounds / SCHEMBL5962921

SCHEMBL5962921

SCHEMBL5962921

N#Cc1ccc(C(=O)c2ccc(O)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.70
▸ CA12 O43570 1/20 0.70
▸ CA3 P07451 1/20 0.70
▸ CA6 P23280 1/20 0.70
▸ CA9 Q16790 1/20 0.70
▸ CA14 Q9ULX7 1/20 0.70
▸ LMNA P02545 2/20 0.65
▸ MAPT P10636 2/20 0.65
▸ HTT P42858 2/20 0.65
▸ ESR1 P03372 1/20 0.65
▸ ESR2 Q92731 1/20 0.65
▸ PKM P14618 1/20 0.65
▸ HPGD P15428 1/20 0.65
▸ MMP3 P08254 1/20 0.61
▸ P4HB P07237 1/20 0.59
▸ CA1 P00915 2/20 0.57
▸ SRD5A2 P31213 1/20 0.56
▸ MAPK1 P28482 1/20 0.54
▸ GSK3B P49841 2/20 0.52
▸ MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3433075 0.91 CA2 (0.67) CA2CA12CA3CA6CA9
4-Cyanophenol SCHEMBL17164639 0.84 CA2 (0.80) CA2CA12CA3CA6CA9
4-Cyanophenol SCHEMBL27294505 0.83 CA2 (1.00) CA2CA12CA3CA6CA9
4-Cyanophenol SCHEMBL50814 0.83 — —
4-Cyanophenol SCHEMBL28811803 0.83 CA2 (1.00) CA2CA12CA3CA6CA9
SCHEMBL3215328 0.83 ALDH1A1 (0.61) CA2LMNAMAPTPKMHPGD
SCHEMBL13284133 0.82 LMNA (0.71) CA2CA12CA3CA6CA9
4-Cyanophenol SCHEMBL4820911 0.81 CA2 (0.84) CA2CA12CA3CA6CA9
SCHEMBL7273846 0.81 CLK1 (0.58) LMNAMAPTHTTESR1ESR2
4-Cyanophenol SCHEMBL27413520 0.81 CA2 (0.94) CA2CA12CA3CA6CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030139349-A1 Benzophenone alpha-d-glycopyranosides, preparation and therapeutic use LABORATORIES FOURNIER SA (FR) 2003-07-24 — — US claimed
EP-1240177-B1 BENZOPHENONE ALPHA-D-GLYCOPYRANOSIDES, PREPARATION AND THERAPEUTIC USE FOURNIER LAB SA (FR) 2003-07-02 — — EP claimed
US-20030100515-A1 Benzophenone glycopyranosides, preparation and therapeutic use LABORATORIES FOURNIER SA (FR) 2003-05-29 — — US claimed
WO-2003002586-A1 [4-(4-CYANOBENZOYL)PHENYL]GLYCOFURANOSIDE DERIVATIVES, USE OF SAID DERIVATIVES AS A MEDICAMENT, PRODUCTION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LABORATOIRES FOURNIER SA (FR) 2003-01-09 — — WO claimed
WO-2003002585-A1 [4-(4-CYANOBENZOYL)PHENYL]GLYCOPYRANOSIDE DERIVATIVES, USE OF SAME AS A MEDICAMENT, PRODUCTION METHOD THEREOF AND COMPOSITIONS LABORATOIRES FOURNIER SA (FR) 2003-01-09 — — WO claimed
EP-1240176-A1 BENZOPHENONE GLYCOPYRANOSIDES, PREPARATION AND THERAPEUTIC USE FOURNIER INDUSTRIE ET SANTE (FR) 2002-09-18 — — EP claimed
EP-1240177-A2 BENZOPHENONE ALPHA-D-GLYCOPYRANOSIDES, PREPARATION AND THERAPEUTIC USE FOURNIER INDUSTRIE ET SANTE (FR) 2002-09-18 — — EP claimed
WO-2001047941-A2 BENZOPHENONE ALPHA-D-GLYCOPYRANOSIDES, PREPARATION AND THERAPEUTIC USE FOURNIER INDUSTRIE ET SANTE (FR) 2001-07-05 — — WO claimed
WO-2001047940-A1 BENZOPHENONE GLYCOPYRANOSIDES, PREPARATION AND THERAPEUTIC USE FOURNIER INDUSTRIE ET SANTE (FR) 2001-07-05 — — WO claimed
EP-4306166-A2 COMPOUNDS, COMPOSITIONS AND METHODS OF USE Aquinnah Pharmaceuticals Inc. (US) 2024-01-17 — — EP disclosed
EP-4306166-A2 COMPOUNDS, COMPOSITIONS AND METHODS OF USE Aquinnah Pharmaceuticals Inc. (US) 2024-01-17 — — EP disclosed
US-20230303489-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE AQUINNAH PHARMACEUTICALS INC (US) 2023-09-28 — — US disclosed
US-20230303489-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE AQUINNAH PHARMACEUTICALS INC (US) 2023-09-28 — — US disclosed
EP-3557998-B1 COMPOUNS, COMPOSITIONS AND METHODS OF USE AQUINNAH PHARMACEUTICALS INC (US) 2023-08-16 — — EP disclosed
EP-0849300-A1 Polyurethanes with covalently bound photoinitiator-units BASF AKTIENGESELLSCHAFT (DE) 1998-06-24 — — EP disclosed
US-5637771-A Compound useful for lowering cholesterol HOFFMANN-LA ROCHE INC. (US) 1997-06-10 — — US disclosed
US-5574071-A ADMINISTERING PHENYLALKYLAMINO KETONES HOFFMANN-LA ROCHE INC. (US) 1996-11-12 — — US disclosed
US-5495048-A ANTICHOLESTEROL AGENTS HOFFMANN-LA ROCHE INC. (US) 1996-02-27 — — US disclosed
CN-1103781-A Use of phenalkylamines HOFFMANN LA ROCHE (CH) 1995-06-21 — — CN disclosed
EP-0636367-A1 Use of phenylalkylamines for producing cholesterol lowering agents F. HOFFMANN-LA ROCHE AG (CH) 1995-02-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100515-A1 Benzophenone glycopyranosides, preparation and therapeutic use GYPA, ST6GAL1, MGAT3 CA2 2577/4885CA12 1855/4885CA3 2232/4885
US-20230303489-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE FUS, TFEB, CLN6 CA2 3676/4885CA12 3562/4885CA3 4500/4885
US-20030139349-A1 Benzophenone alpha-d-glycopyranosides, preparation and therapeutic use GYPA, MGAT3, B3GAT3 CA2 3210/4885CA12 2725/4885CA3 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.